DeepMed Research

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

IUdR/BUdR Cell Cycle Labelling

Not Applicable

Completed

Conditions: Hematologic Malignancies

First Posted Date: 2002-07-26

Last Posted Date: 2012-01-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 28

Registration Number: NCT00042250

Locations: 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States

Outpatient Treatment Of Deep Venous Thrombosis Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients

Phase 2

Terminated

Conditions: Deep Vein Thrombosis
Neoplasms

Interventions: Drug: Dalteparin (Fragmin)

First Posted Date: 2002-07-19

Last Posted Date: 2018-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 26

Registration Number: NCT00041782

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia

Phase 1

Completed

Conditions: Leukemia, Myeloid, Chronic

Interventions: Drug: Zarnestra (R115777)
Drug: Gleevec (Imatinib mesylate)

First Posted Date: 2002-06-21

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 26

Registration Number: NCT00040105

Locations: 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States

Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies

Not Applicable

Terminated

Conditions: Leukemia, Lymphocytic, Chronic
Leukemia, Lymphocytic, Acute
Lymphoma, T-Cell
Lymphoma, B-Cell
Lymphoma, Low-Grade

Interventions: Drug: Campath-1H

First Posted Date: 2002-06-07

Last Posted Date: 2018-11-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 19

Registration Number: NCT00038883

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes

Not Applicable

Withdrawn

Conditions: Acute Myelogenous Leukemia
Chronic Myelogenous Leukemia

Interventions: Biological: Dendritic Cell Activated Lymphocyte

First Posted Date: 2002-06-07

Last Posted Date: 2018-10-25

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00038870

CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation

Not Applicable

Terminated

Conditions: Chronic Myelogenous Leukemia
Multiple Myeloma
Non Hodgkin's Lymphoma
Hodgkin's Disease
Chronic Lymphocytic Leukemia

Interventions: Biological: CD8 Depleted Donor Lymphocyte

First Posted Date: 2002-06-07

Last Posted Date: 2012-08-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT00038818

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases

Phase 2

Completed

Conditions: Leukemia
Lymphoma

Interventions: Procedure: Megadose of CD34 Selected Progenitor Cells
Drug: Melphalan
Drug: Thiotepa
Drug: Fludarabine
Drug: Rabbit ATG

First Posted Date: 2002-06-07

Last Posted Date: 2012-08-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 29

Registration Number: NCT00038857

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD

Phase 1

Terminated

Conditions: Acute Graft Versus Host Disease

Interventions: Drug: Recombinant Human Keratinocyte Growth Factor

First Posted Date: 2002-06-07

Last Posted Date: 2012-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT00038792

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS

Phase 1

Completed

Conditions: Acute Myelogenous Leukemia
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia

Interventions: Drug: Mylotarg
Drug: Fludarabine
Drug: Melphalan
Drug: Anti-thymocyte globulin
Procedure: Stem cell transplant

First Posted Date: 2002-06-07

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 47

Registration Number: NCT00038831

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Safety and Efficacy of Campath in Nonmyeloablative Transplantation

Not Applicable

Completed

Conditions: Lymphoma
Leukemia

Interventions: Drug: Campath-1 H (Alemtuzumab)
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Rituximab

First Posted Date: 2002-06-07

Last Posted Date: 2011-11-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 65

Registration Number: NCT00038844

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy